Find Academic Supervisors

Björn Pasternak is a Research Professor leading the Pharmacoepidemiology group at the Department of Medicine, Solna, Karolinska Institutet. His team specializes in large-scale registry studies focused on adverse drug effects, with research programs in pediatric pharmacoepidemiology, safety of diabetes medications, and rapid assessment of drug safety concerns. The group leverages high-quality epidemiological methods to inform evidence-based clinical decisions. Pasternak's research interests span pharmacoepidemiology, drug safety, diabetes outcomes, cardiovascular risk, and perinatal health. His work utilizes nationwide registries to evaluate real-world drug effects, socioeconomic disparities in treatment, and long-term outcomes of chronic therapies. Key focuses include GLP-1 receptor agonists, SGLT2 inhibitors, antibiotic use in pregnancy, and opioid safety. Recent publications demonstrate strong emphasis on Scandinavian cohort studies of diabetes medications (GLP-1 agonists, SGLT2 inhibitors) and their associations with thyroid cancer, liver events, intestinal obstruction, and cardiovascular/renal outcomes. Other trends include perinatal pharmacovigilance (antibiotics, acid-suppressive drugs) and neurodegenerative risks in athletes.

• Pharmacoepidemiology
• Drug Safety
• Diabetes Mellitus
• +3 more

Sara Hägg is a Senior Lecturer at the Karolinska Institutet , affiliated with the Department of Medical Epidemiology and Biostatistics . She is also a Docent in molecular epidemiology. PhD in Computational Biology (Linköping University, 2009) MSc in Molecular Biology (Stockholm University, 2003) BSc in Computer Science (Stockholm University, 2003) Her research focuses on human biological aging , including measurement of aging markers (telomere length, epigenetic clocks, frailty index), causal pathway analysis, and identification of geroprotectors for age-related diseases. She utilizes longitudinal twin studies (SATSA, GENDER, HARMONY), UK Biobank, and Swedish cohorts with methods like Mendelian randomization and genome-wide analyses . Recent articles demonstrate trends in epidemiological aging research , with emphasis on cardiovascular aging , neurological disease interactions , metabolic profiling , and epigenetic clocks . Her work often involves multivariable modeling and cross-cohort validation . Leadership roles include Director of LifeGene Core Facility (2024-) and Founding Board Member of the Nordic Aging Society (2023-). She serves on expert groups for the Swedish Twin Registry and Strategic Research Area in Epidemiology and Biostatistics .

• Epidemiology
• Gerontology
• Medical Genetics and Genomics
• +3 more

Mattias Brunström serves as Assistant Professor of Cardiology and Associate Professor of Epidemiology at Umeå University's Faculty of Medicine within the Department of Public Health and Clinical Medicine, Section of Cardiology. He is concurrently a resident physician at Norrlands University Hospital and holds leadership roles as chairman of Sweden's national hypertension working group and scientific secretary of the Swedish Society for Hypertension, Stroke and Vascular Medicine, with active participation in the European and International Societies of Hypertension. His academic foundation includes a 2018 PhD thesis examining blood pressure-lowering treatment effects across different blood pressure levels through systematic reviews and meta-analyses of randomized clinical trials. This doctoral work established his expertise in evidence-based cardiovascular therapeutics and epidemiological methodology. Dr. Brunström's research program centers on cardiovascular disease risk factors, with specialized focus on hypertension pathophysiology and aortic diseases. His group investigates how adolescent blood pressure levels predict future cardiovascular events, examining interactions with obesity, physical fitness, and diabetes to improve risk stratification. They also analyze differential effects of antihypertensive drug classes on cardiovascular outcomes and study risk factors for aortic dissection/rupture to optimize preventive surgical interventions. This work addresses critical gaps in managing the world's leading cause of death, where uncontrolled hypertension contributes to 10 million annual fatalities despite effective treatments. Analysis of his 2024-2025 publications reveals dominant themes in hypertension guideline development, treatment threshold controversies, and cardiovascular risk assessment. His work frequently challenges conventional approaches (e.g., questioning excessive treatment of 'elevated' blood pressure in elderly patients) while advancing evidence for lifestyle interventions and beta-blocker utility. Methodologically, his research leverages large cohort studies (including 1.4 million enlistee data), systematic reviews, and international collaborations through societies like ESH and ISH to translate epidemiological findings into clinical practice. Dr. Brunström leads multiple funded research initiatives including 'Remission of type 2 diabetes through eHealth' (2022-2028) and 'VIPviza' (2013-2027), directing a multidisciplinary team that bridges clinical cardiology, epidemiology, and public health. His advisory role extends to national guideline committees and international hypertension societies where he shapes clinical practice through evidence synthesis and position papers. Based at Norrlands University Hospital's Cardiology Section, his research group operates within Umeå University's strong cardiovascular research ecosystem, maintaining active collaborations with the Swedish National Diabetes Register and international consortia. Their work emphasizes real-world applicability, examining topics like bedtime dosing of antihypertensives and self-report diagnostic tools to overcome barriers in hypertension control where only 25% of affected individuals achieve target blood pressure levels.

• Cardiovascular Disease
• Hypertension
• Aortic Diseases
• +3 more

Nanbo Zhu is a Postdoctoral Researcher at Karolinska Institutet, jointly affiliated with the Department of Neurobiology, Care Sciences and Society (primary appointment until 2026) and the Department of Medical Epidemiology and Biostatistics (appointment until 2025). He conducts research within the Maria Eriksdotter research group (focused on clinical geriatrics) and Zheng Chang's psychiatric and pharmaco-epidemiology group. His research specializes in the intersection of mental health and chronic diseases , with emphasis on: Epidemiological patterns of mental illness in chronic kidney disease (CKD) patients Pharmacoepidemiology of psychiatric medications (antidepressants, ADHD drugs, benzodiazepines) Drug safety profiles in vulnerable populations including elderly and renal impairment patients Advanced methodologies like target trial emulation using registry data Zhu's publications demonstrate consistent focus on neuropsychiatric comorbidities in somatic conditions, pharmacotherapy outcomes, and population health in Chinese cohorts. His work frequently utilizes large-scale registries and emphasizes clinical implications of mental health management in chronic disease populations.

• Epidemiology
• Nephrology
• Psychiatry
• +3 more

Anne-Laure Faucon is a Postdoctoral Researcher in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet, Stockholm. She is also a senior nephrologist specialized in clinical nephrology and renal physiology. Her current position at Karolinska Institutet began in 2022, following a postdoctoral position at Paris-Saclay University from 2020-2022. Her educational background includes: PhD in renal epidemiology, Paris-Saclay University (2017-2020) Master of sciences in epidemiology-biostatistics, Paris-Saclay University (2017) Master of sciences in renal physiology, Paris-Descartes University (2013) Specialization in Nephrology and Doctor of Medicine (2014) Residency (2009-2014) Anne-Laure's research focuses on chronic kidney disease (CKD) across its different stages, etiologies, and complications. She aims to identify modifiable risk factors and biomarkers of CKD progression, contribute to better characterization of CKD prognosis, improve risk stratification, and assess real-life clinical management associated with improved outcomes. She bridges clinical nephrology, physiology, and epidemiology-biostatistics, applying causal inference methods to large healthcare cohort and registry data including the French NephroTest and CKD-REIN cohorts, Swedish Renal Registry, Stockholm CREAtinine Measurement project, and the Swedish KIdney Pathology cohort. Her recent publications demonstrate a strong focus on kidney function metrics, CKD progression, cardiovascular complications in kidney disease, and the intersection of kidney disease with other conditions like inflammatory bowel disease and lupus nephritis. She frequently utilizes large Swedish registry data including the Stockholm CREAtinine Measurements (SCREAM) project. Anne-Laure has received notable recognition including the upcoming ERA Curatorium Award for Young Investigators – Young Nephrologist (2025) and being named a Laureate of the French National Academy of Medicine for her work in renal physiology. She currently supervises three doctoral students (Antoine Créon, Aurora Caldinelli, and Charikleia Chrysostomou) and has previously supervised several other researchers. Anne-Laure also teaches renal physiology at Karolinska Institutet since 2024, continuing her previous teaching roles at the Paris Medical School. She is part of the Cardio-renal epidemiology research group led by Juan-Jesus Carrero at Karolinska Institutet, focusing on the intersection of kidney and cardiovascular diseases.

• Epidemiology
• Nephrology
• Renal Epidemiology
• +3 more

Juan-Jesus Carrero is a Professor in cardio-renal epidemiology at Karolinska Institutet’s Department of Medical Epidemiology and Biostatistics, with additional roles as Senior Researcher at Danderyd Hospital’s Division of Renal Medicine and Lektor at Örebro University School of Medicine. His research focuses on improving prevention and management of chronic kidney disease (CKD), integrating kidney function into clinical decision-making. He has authored over 550 articles and 30 book chapters, with 70,000+ citations and an H-index of 94. Key engagements include co-directing the ISRNM educational program, guideline development for KDIGO and ESPEN, and editorial roles at European Heart Journal and Nephrology Dialysis Transplantation . Education includes a PhD in Medicine (2008, Karolinska Institutet) and Pharmacy (2005, University of Granada). Awards include the 2021 ERA Research Excellence Award and US National Kidney Foundation’s Distinguished Fellow designation. Current research leverages national healthcare registries like the Swedish Renal Registry and SCREAM project to study CKD progression, cardio-renal interactions, and modifiable risk factors (diet, medications). Collaborates with global networks and welcomes partnerships in cardiorenal epidemiology. Advised 8 PhD students (e.g., Marco Trevisan, Björn Runesson) and supervises 5 current candidates (Mikael Eklund, Alessandro Bosi). Postdoctoral researchers include Faizan Mazhar and affiliated scholars at Harvard/PEKing universities. Grants include studies on anticoagulant safety, sex differences in kidney disease, and protein-energy wasting. Labs collaborate with biostatisticians like Prof. Arvid Sjölander to advance methodological rigor.

• Cardio-renal epidemiology
• Chronic Kidney Disease (CKD)
• Nephrology
• +5 more

Aleksandra Antovic is an Adjunct Senior Lecturer (Docent) at Karolinska Institutet and a Senior Consultant in Rheumatology at Karolinska University Hospital. Since 2024, she has served as the research group leader for the SLE/APS/ANCA-vasculitis group within the Department of Medicine, Solna. Her work bridges clinical rheumatology with research in autoimmune diseases, particularly focusing on vascular complications in systemic inflammatory conditions. Dr. Antovic earned her Doctor of Philosophy from the Department of Surgical Science at Karolinska Institutet in 2004 and was awarded Docent status in 2015. She has received recognition including the Pedagogic Award at Karolinska Institutet's Department of Medicine Huddinge in 2016. Her primary research interests center on systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and ANCA-associated vasculitis (AAV), with particular focus on thromboembolic manifestations in these conditions. Through longitudinal studies of well-characterized patient cohorts, she has identified four autoantibody-defined subgroups among SLE patients and investigates how these subgroups differ in symptoms, inflammation types, and genetics. Her work spans clinical studies, translational projects with molecular immunologists and geneticists, and patient-centered research on educational needs and perceptions. Dr. Antovic's research has highlighted the importance of vascular complications in rheumatic diseases, expanding this research area across multiple collaborative groups. She has been awarded the Scandinavian Research Foundation/Scandinavian Journal of Rheumatology's award for successful research in rheumatology. As an educator, she has supervised numerous PhD students both as main supervisor and co-supervisor, with projects focusing on hemostatic disturbances, pregnancy complications, and autoimmune conditions. Her current grants investigate thrombotic complications in rheumatic diseases, SLE subgrouping, and predictors of venous thromboembolism. The SLE/APS/Vasculitis research group she leads consists of approximately 20 members including clinical researchers, postdocs, doctoral students, research nurses, and a research patient partner. The group conducts clinical research primarily on SLE, APS, and AAV, often in collaboration with molecular immunologists, geneticists, and epidemiologists.

• Autoimmunity and Inflammation
• Clinical Laboratory Medicine
• Rheumatology
• +5 more

Patrik Rydén is a Professor of Mathematical Statistics at the Department of Mathematics and Mathematical Statistics, Umeå University, where he applies statistical methods to complex datasets. He also directs the Industrial Doctoral School for Research and Innovation , fostering academia-industry collaboration. His research spans healthcare (ambulance logistics, cancer diagnostics), industrial optimization (automotive quality control), and bioinformatics. Research Focus Rydén develops data-driven methodologies for: Healthcare : Optimizing ambulance deployment, predicting patient care times, and modeling disease spread. Industry : Statistical process control for manufacturing and quality improvement. Bioinformatics : Cancer subtype identification and vaccine efficacy modeling. Publication Trends His recent work emphasizes applied statistics in healthcare (40%), industrial machine learning (30%), and genomic analysis (30%), with strong themes in predictive modeling, spatio-temporal analysis, and high-dimensional data interpretation. Leadership & Projects As director of the Industrial Doctoral School, he bridges academic research with industry needs. Key projects include: Predicting post-anesthesia care time using ML (2022–2027) Data-driven prehospital care optimization (2018–2028) Statistical learning for industrial defect detection (2017–2023)

• Mathematical Statistics
• Data Analysis
• Ambulance Care Optimization
• +3 more

Professor Jonas Klingström is affiliated with Linköping University's Department of Biomedical and Clinical Sciences (BKV), within the Faculty of Medicine and Health Sciences. His research focuses on understanding the mechanisms of zoonotic viruses, particularly hantaviruses and coronaviruses, investigating how these pathogens modulate inflammatory responses and cell-cell signaling. Key interests include viral pathogenesis, immune system interactions, and developing treatments for hantavirus-related diseases like hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). His work combines clinical samples from patients with in vitro models using primary endothelial and immune cells. Notable contributions include elucidating the role of IL-6 trans-signaling in hantavirus-induced barrier dysfunction and identifying immunological factors linked to disease severity. Research also extends to SARS-CoV-2, examining immune responses in immunocompromised individuals and vaccine efficacy. Professor Klingström leads the Molecular Medicine and Virology Division (MMV), integrating molecular biology studies with biomedical education programs. His team collaborates on antiviral drug discovery, such as macropinocytosis inhibitors, and improving viral isolation logistics for public health applications. Recent publications span hantavirus classification updates, SARS-CoV-2 immune correlates, and viral protein network analyses. No scientific awards are explicitly listed in the provided text. His research group actively explores translational approaches to combat viral diseases through a combination of fundamental science and clinical relevance.

• Zoonotic Viruses
• Hantavirus Pathogenesis
• Coronavirus Immunology
• +3 more

Fahim Ebrahimi is a Postdoctoral Researcher at Karolinska Institutet's Department of Medical Epidemiology and Biostatistics, working within Jonas Ludvigsson's Gastrointestinal Epidemiology research group. His research spans multiple disciplines including hepatology, gastroenterology, endocrinology, and epidemiology, with a particular focus on metabolic dysfunction-associated steatotic liver disease (MASLD), inflammatory bowel disease, and their systemic complications. His primary research interests include: Gastrointestinal epidemiology and disease patterns MASLD/NAFLD progression and complications Inflammatory bowel disease and associated conditions Cardiovascular risks in metabolic and gastrointestinal disorders Maternal-fetal health outcomes related to liver disease Dr. Ebrahimi's recent publications (2023-2025) demonstrate a strong focus on nationwide cohort studies examining the long-term consequences of MASLD, inflammatory bowel disease, and related conditions. His work frequently employs population-based methodologies to investigate connections between gastrointestinal diseases and systemic complications including cardiovascular events, cancer risk, and mortality. His research shows particular strength in multigenerational studies examining familial patterns of disease. His scientific contributions include: Multiple publications in high-impact journals including Gastroenterology, Lancet Regional Health, and Journal of Clinical Endocrinology & Metabolism Research examining bidirectional disease associations (e.g., between microscopic colitis and primary sclerosing cholangitis) Studies on the impact of MASLD across multiple organ systems Investigations into maternal-fetal health outcomes related to liver disease Dr. Ebrahimi has secured competitive research funding from the Swiss National Science Foundation and the Swiss Academy of Medical Sciences for projects including 'Characterization of Determinants of Disease Occurrence, Progression and Adverse Clinical Outcomes in Metabolic-Associated Fatty Liver Disease' and 'Effects of IL-1 Beta on the hypothalamic-pituitary-gonadal (HPG) axis in men with obesity and metabolic syndrome.'

• Gastrointestinal Epidemiology
• Metabolic Dysfunction-Associated Steatotic Liver Disease
• Inflammatory Bowel Disease
• +4 more

Hans Friberg is an Adjunct Professor in Anesthesiology and Intensive Care at Lund University, serving as Consultant and Project Manager for the Center for Cardiac Arrest and SWECRIT (Swedish Critical Care Registry). His work advances UN Sustainable Development Goals related to health through critical care research and registry-based initiatives. His research centers on cardiac arrest pathophysiology and treatment, with expertise in out-of-hospital resuscitation, targeted temperature management, and biomarker development for brain injury and organ dysfunction. Key focus areas include prognostication methods, hypothermia protocols, and long-term cognitive/physical recovery in survivors. Recent publications emphasize biomarker applications in critical care settings, including calprotectin for sepsis diagnosis, cystatin C for renal risk stratification, and neurofilament for neurological outcomes. His work leverages large-scale registry data (SWECRIT) to identify risk factors and evaluate interventions across diverse critical illness populations. Scientific Awards: No major awards or fellowships are documented in the provided profile. Professor Friberg has supervised 12 doctoral students across critical care topics including acute kidney injury biomarkers, post-ICU recovery, and sepsis pathophysiology. He leads active projects such as the SWECRIT Covid-19 cohort study and contributes to international trials like TTM2, with funding from institutional and registry-based sources. He operates through the Center for Cardiac Arrest and SWECRIT collaborative networks, which integrate 30+ Swedish intensive care units to drive registry-based research on resuscitation science and critical care delivery optimization.

• Cardiac Arrest
• Resuscitation
• Anesthesiology and Intensive Care
• +5 more

Francesco Cosentino is a Professor of Clinical Cardiovascular Research and Senior Physician at Karolinska Institutet's Department of Medicine, Solna. He leads the Molecular Cardiology Research Group, focusing on cardiovascular mechanisms linked to diabetes, obesity, and aging. His work bridges molecular epigenetics and clinical outcomes, particularly the interplay of environmental factors and genetic pathways in cardiovascular disease pathogenesis. Research interests include epigenetic regulation of vascular dysfunction, oxidative stress, and inflammation in metabolic disorders. Notable contributions include advancing ESC guidelines on diabetes and cardiovascular care, emphasizing novel glucose-lowering therapies like SGLT2 inhibitors and GLP-1 agonists for cardioprotection. Key achievements include the 2022 Doctor Honoris Causa from Victor Babeș University. His translational research program integrates clinical trials, animal models, and patient cohorts to identify epigenetic biomarkers for cardiovascular risk stratification. Funding sources include the Swedish Research Council, Swedish Heart & Lung Foundation, and international collaborations. He advises PhD students and postdoctoral researchers in molecular cardiology and epigenetics, mentoring the next generation of cardiovascular scientists. The Molecular Cardiology Group hosts a dynamic team exploring chromatin remodeling, vascular aging, and gene-environment interactions. Current projects investigate epigenetic modifiers as therapeutic targets and the transgenerational effects of metabolic diseases.

• Cardiology and Cardiovascular Disease
• Medical Epigenetics
• Metabolic Disorders
• +3 more

Rachel Fisher is a Professor of Cardiovascular Diseases at Karolinska Institutet's Department of Medicine, Solna, since 2009. She leads the 'Lipid handling in health and cardiometabolic disease' research group within the Carolina Hagberg team. Her work focuses on molecular mechanisms linking lipid metabolism disturbances to cardiovascular diseases and type 2 diabetes, with a particular emphasis on adipose tissue dysfunction and inflammatory processes. Education includes a Docent degree from Karolinska Institutet (2003). Her research spans lipid biochemistry, adipocyte biology, and translational studies on chronic diseases, including obesity, diabetes, and atherosclerosis. Collaborative projects often involve clinical cohorts and molecular techniques. Recent publications highlight her work on ANGPTL3/8 in atherogenesis, gene expression in breast reconstruction, and in vitro adipocyte models. Her research integrates epidemiological insights with cellular mechanisms, emphasizing the role of ceramides, sphingolipids, and microRNAs in disease pathways. Her lab's work also explores physical activity interventions (e.g., telomere length in older adults) and the functional implications of chronic kidney disease on adipose tissue. She contributes to the European Lipoprotein Club and has co-authored reviews on adipose tissue vasculature and fatty acid transport proteins.

• Cardiovascular Diseases
• Lipid Metabolism
• Diabetes
• +3 more

Henrik Holmberg is an Associate Professor at the Department of Epidemiology and Global Health, Umeå University. His primary affiliation is with Umeå University's medical faculty, focusing on epidemiological research with a strong emphasis on surgical outcomes, geriatric medicine, and public health. His research spans multiple disciplines including clinical epidemiology, health services research, and population health. Key research areas include: surgical outcomes after hernia repair, hematological disorders (e.g., myeloproliferative neoplasms), exercise interventions for older adults, and dementia care. He has conducted extensive work using national registries (e.g., Swedish Hernia Register) to analyze healthcare quality, treatment efficacy, and patient-reported outcomes. His recent publications emphasize high-impact surgical topics like groin hernia repair complications, thromboembolic event prediction in blood disorders, and the effects of intensive exercise programs on cognitive and physical function in aging populations. Collaborative projects include the Umeå HIT Study (high-intensity interval training for seniors) and the VIPVIZA trial assessing risk communication in cardiovascular care. Awards: No specific prizes or fellowships highlighted in the provided texts. Grants and advising: Active involvement in multi-center clinical trials and registry studies. Supervised numerous studies on healthcare quality and aging-related interventions but no explicit student names listed here. Labs/Teams: Core member of the Umeå University epidemiology group, collaborating with teams in surgery, geriatrics, and hematology. Research infrastructure includes access to national health registries and interdisciplinary clinical research networks.

• Epidemiology
• Surgical Outcomes
• Public Health
• +3 more

Jana de Boniface is a Research Professor at Karolinska Institutet within the Department of Medical Epidemiology and Biostatistics. She leads a research group focused on optimizing breast cancer surgery through clinical trials and registry studies. Her work aims to de-escalate surgical interventions, minimize adverse effects on quality of life, and maintain oncological safety. Research Focus: Her primary interests include axillary surgery de-escalation (e.g., SENOMAC trial), targeted lymph node techniques (AXSANA study), exercise interventions during neoadjuvant therapy (Neo-ACT trial), and breast reconstruction outcomes. She emphasizes patient-reported outcomes and international collaboration across Europe. Publication Trends: Recent articles (2024–2025) predominantly explore axillary management refinements, breast reconstruction complications, treatment strategies for triple-negative breast cancer in elderly patients, and standardization of outcome reporting in clinical trials. A strong emphasis is placed on surgical de-escalation, precision techniques, and quality-of-life metrics. Collaborations & Leadership: She coordinates multinational studies like SENOMAC and AXSANA, collaborating with epidemiologists, oncologists, and radiologists. Her group investigates radiotherapy impacts, marker localization technologies, and patient experiences post-surgery.

• Breast Cancer Surgery
• Oncological Safety
• Patient Quality of Life
• +3 more